Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Income from Continuing Operations (2020 - 2025)

Cytek Biosciences' Income from Continuing Operations history spans 6 years, with the latest figure at 44076000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 558.98% year-over-year to 44076000.0; the TTM value through Dec 2025 reached 66486000.0, down 992.98%, while the annual FY2025 figure was 66539000.0, 1005.3% down from the prior year.
  • Income from Continuing Operations reached 44076000.0 in Q4 2025 per CTKB's latest filing, down from 5469000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 9603000.0 in Q4 2024 to a low of 44076000.0 in Q4 2025.
  • Average Income from Continuing Operations over 5 years is 3962300.0, with a median of 1661500.0 recorded in 2021.
  • The largest YoY upside for Income from Continuing Operations was 419.14% in 2022 against a maximum downside of 2215.69% in 2022.
  • A 5-year view of Income from Continuing Operations shows it stood at 1165000.0 in 2021, then soared by 419.14% to 3718000.0 in 2022, then skyrocketed by 48.01% to 5503000.0 in 2023, then soared by 74.5% to 9603000.0 in 2024, then tumbled by 558.98% to 44076000.0 in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Income from Continuing Operations are 44076000.0 (Q4 2025), 5469000.0 (Q3 2025), and 5575000.0 (Q2 2025).